

Safety of Remimazolam in Vulnerable Populations [Corrigendum]

Ge JY, Deng BR, Cao XH, Liu XJ. *Drug Des Devel Ther.* 2025;19:8691–8709.

Page 8698, Kidney Disease, second paragraph, line 4, the text “remifentanil group” should read “remimazolam group”.

The authors apologize for this error.

Drug Design, Development and Therapy

Dovepress
Taylor & Francis Group**Publish your work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S576305>

Drug Design, Development and Therapy 2025:19 9683

9683

Received: 23 October 2025
Accepted: 23 October 2025
Published: 29 October 2025



© 2025 Ge et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (<http://creativecommons.org/licenses/by-nc/4.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).